http://ipkitten.blogspot.com/2025/07/pitfalls-of-cell-therapy-manufacturing.html
The recent Board of Appeal decision in T 0868/23 is a powerful example of the potential fragility of process IP in the field of cell therapy. The decision in T 0868/23 illustrates how a cell therapy process invention may evolve over time to the detriment of the IP. Processes can be notoriously difficult to pin down, leaving even seemingly broad claims vulnerable to attack in the
Content reproduced from The IPKat as permitted under the Creative Commons Licence (UK).
